Edgewise Therapeutics (EWTX) Equity Ratio (2020 - 2026)

Edgewise Therapeutics has disclosed Equity Ratio across 7 years of filings, most recently posting 0.95 for Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.95, up 0.58% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.95 (up 0.58% YoY), and the FY2025 annual result was 0.95, changed 0.19% from the prior year.
• Equity Ratio came in at 0.95 for Q1 2026 at Edgewise Therapeutics, up from 0.95 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.97 in Q1 2024 to a low of 0.93 in Q3 2023.
• The 5-year median for Equity Ratio is 0.95 (2026), against an average of 0.95.
• Across the five-year window, Equity Ratio decreased 3.03% in 2022 and rose 2.51% in 2024, its largest moves.
• Edgewise Therapeutics' Equity Ratio stood at 0.94 in 2022, then retreated by 0.72% to 0.94 in 2023, then advanced by 0.6% to 0.94 in 2024, then gained by 0.19% to 0.95 in 2025, then climbed by 0.64% to 0.95 in 2026.
• The last three Equity Ratio figures came in at 0.95 (Q1 2026), 0.95 (Q4 2025), and 0.96 (Q3 2025), per Business Quant data.